Drug Profile
Research programme: cancer therapeutic vaccine - Amal Therapeutics
Alternative Names: ATP 124; Peptide-based vaccines - Amal TherapeuticsLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Amal Therapeutics
- Class Cancer vaccines; Protein vaccines; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Colorectal cancer; Glioblastoma
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in Switzerland
- 02 May 2019 Amal Therapeutics and Boehringer Ingelheim plan the phase Ib KISIMA-01 trial for Colorectal cancer (Late-stage disease, Monotherapy, Combination therapy) in July 2019
- 02 May 2019 Research programme: cancer therapeutic vaccine - Amal Therapeutics is available for licensing as of 02 May 2019. https://amaltherapeutics.com/partnering/